VINFOSILTINE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C51H72N5O10P
Molecular Weight	946.1186
Optical Activity	UNSPECIFIED
Defined Stereocenters	10 / 10
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12N3CC[C@@]14C5=C(C=C(OC)C(=C5)[C@]6(C[C@@]7([H])CN(C[C@](O)(CC)C7)CCC8=C6NC9=C8C=CC=C9)C(=O)OC)N(C)[C@@]4([H])[C@](O)([C@H](O)[C@]2(CC)C=CC3)C(=O)N[C@H](C(C)C)P(=O)(OCC)OCC

InChI

InChIKey=BOELCLFVOBIXIF-MAKKXPIGSA-N

InChI=1S/C51H72N5O10P/c1-10-47(60)27-32-28-50(46(59)64-9,40-34(19-23-55(29-32)30-47)33-17-14-15-18-37(33)52-40)36-25-35-38(26-39(36)63-8)54(7)43-49(35)21-24-56-22-16-20-48(11-2,42(49)56)44(57)51(43,61)45(58)53-41(31(5)6)67(62,65-12-3)66-13-4/h14-18,20,25-26,31-32,41-44,52,57,60-61H,10-13,19,21-24,27-30H2,1-9H3,(H,53,58)/t32-,41-,42-,43+,44+,47-,48+,49+,50-,51-/m0/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7882462

Vinfosiltine (also known as S 12363) was developed as a vinca alkaloid derivative. It is known that vinca alkaloids are widely used in the medical treatment of breast cancer. Vinfosiltine participated in the phase II clinical trial to treat the patients with advanced breast cancer. The results have shown that the drug didn’t have significant single-agent activity. As a result, the development of vinfosiltine was discontinued.

Approval Year

PubMed

Title	Date	PubMed

Sample Use Guides

In Vivo Use Guide

a randomization was performed between two schedules with the same dose intensity, that is, 0.3 mg/m2 given weekly or 0.6 mg/m2 given every 2 weeks

Route of Administration: Intravenous

Name

Type

Language

VINFOSILTINE

Official Name

English

vinfosiltine [INN]

Common Name

English

(23(S))-4-DEACETYL-3-DE(METHOXYCARBONYL)-3-((2-METHYL-1-PHOSPHONOPROPYL)CARBAMOYL)VINCALEUKOBLASTINE, DIETHYL ESTER

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C932